Venus Concept (VERO) AI Stock Analysis

• Market Cap: $4.11M
• Dividend Yield: N/A
• Average Volume (3M): 141.32K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.22
• Revenue Growth: -13.90%
• EPS Growth: 44.89%
• Country: US
• Employees: 292
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -8.03
• Shares Outstanding: 1,859,123
• 10 Day Avg. Volume: 313,727
• 30 Day Avg. Volume: 141,323
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 8.79
• Enterprise Value/Revenue: 0.60
• Enterprise Value/Gross Profit: 0.93
• Enterprise Value/Ebitda: -1.12
• 1Y Price Target: $4.30
• Price Target Upside: 96.35% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 45 Neutral
• Price Target: $2.50 ▲(14.16% Upside)

Venus Concept's overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues, high costs, and significant net losses. Technical analysis and valuation provide little support, with neutral indicators and a negative P/E ratio. The earnings call highlights some strategic efforts but also underscores ongoing challenges, contributing to a cautious outlook.

Positive Factors

Strategic Business Sale

The sale of the Venous Hair business allows Venus Concept to focus on core medical aesthetics, potentially improving revenue growth, lowering operating expenses, and enhancing cash flow.

Quarterly Revenue Growth

The sequential revenue growth reflects strong execution and resilience in a challenging market, indicating potential for recovery and expansion in the core business.

Cash System Sales Increase

The shift towards higher quality cash revenues in the U.S. market suggests a strategic focus on more profitable sales channels, enhancing long-term revenue stability.

Negative Factors

High Leverage

The high leverage ratio suggests significant financial risk, potentially limiting the company's ability to invest in growth opportunities and manage economic downturns.

Declining Revenue

The year-over-year decline in revenue highlights ongoing challenges in maintaining market share and growth, which could impact long-term competitiveness and financial health.

Operating Losses

Increased operating losses indicate persistent inefficiencies and cost management issues, which could hinder profitability and sustainability in the long run.

Venus Concept Business Overview & Revenue Model

Company Description

Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes aesthetic device platforms, including Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; and Venus Viva, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss, a device for non-invasive lipolysis of the abdomen and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; and ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles. The company is headquartered in Toronto, Canada.

How the Company Makes Money

Venus Concept generates revenue through multiple streams, primarily by selling its proprietary medical devices and systems to aesthetic practitioners and clinics. These devices are often sold with accompanying service and maintenance agreements, which provide ongoing revenue. Additionally, the company offers consumables and accessories related to their devices, creating a recurring revenue model. Partnerships with aesthetic practices and medical professionals also enhance their market reach and revenue potential. Furthermore, Venus Concept may benefit from collaborations with research institutions and participation in clinical trials to validate and promote the effectiveness of its products, driving further sales and brand recognition.

Venus Concept Financial Statement Overview

Summary

Venus Concept faces significant financial challenges, with declining revenues, high operational costs, and substantial net losses. The balance sheet shows high leverage and low equity, posing risks to financial stability. Cash flow management remains a concern despite some improvement in free cash flow.

Income Statement

Venus Concept's income statement reveals significant challenges. The company has experienced declining revenue over the past few years, with a TTM revenue growth rate of -1.46%. Profitability metrics are concerning, with a TTM net profit margin of -81.26% and negative EBIT and EBITDA margins, indicating operational inefficiencies and high costs relative to revenue. Despite a relatively strong gross profit margin of 67.90% in the TTM period, the overall financial health is weakened by substantial net losses.

Balance Sheet

The balance sheet highlights financial instability, with a very high debt-to-equity ratio of 17.05 in the TTM period, suggesting significant leverage and potential risk in meeting debt obligations. The return on equity is negative, reflecting losses and poor returns for shareholders. The equity ratio is low, indicating a heavy reliance on debt financing. These factors point to financial vulnerability and potential liquidity issues.

Cash Flow

Cash flow analysis shows some improvement in free cash flow growth, with a TTM growth rate of 29.09%. However, the operating cash flow remains negative, and the operating cash flow to net income ratio is -0.41, indicating cash flow challenges. The free cash flow to net income ratio is slightly positive at 1.01, suggesting that free cash flow is marginally covering net losses. Overall, cash flow management remains a concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	60.11M	64.83M	76.35M	99.50M	105.62M	78.01M
Gross Profit	39.00M	44.31M	52.17M	65.97M	74.09M	51.39M
EBITDA	-32.31M	-36.04M	-26.11M	-35.28M	-13.04M	-68.49M
Net Income	-41.34M	-47.00M	-37.25M	-43.58M	-23.01M	-82.82M
Balance Sheet
Total Assets	63.09M	68.18M	93.65M	125.38M	157.37M	160.53M
Cash, Cash Equivalents and Short-Term Investments	3.88M	4.27M	5.40M	11.57M	30.88M	34.30M
Total Debt	37.06M	43.03M	79.70M	83.77M	77.87M	79.60M
Total Liabilities	60.31M	65.35M	107.10M	116.64M	112.27M	116.76M
Stockholders Equity	2.33M	2.37M	-14.02M	8.09M	40.94M	44.23M
Cash Flow
Free Cash Flow	-18.89M	-11.19M	-12.97M	-27.32M	-20.28M	-28.94M
Operating Cash Flow	-18.61M	-11.07M	-12.86M	-26.98M	-19.77M	-28.65M
Investing Cash Flow	-273.00K	-123.00K	-116.00K	-336.00K	-552.00K	-2.39M
Financing Cash Flow	18.02M	10.06M	6.80M	8.01M	16.82M	49.67M

Venus Concept Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.19
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VERO, the sentiment is Negative. The current price of 2.19 is below the 20-day moving average (MA) of 2.35, below the 50-day MA of 2.34, and below the 200-day MA of 2.81, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 40.30 is Neutral, neither overbought nor oversold. The STOCH value of 11.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VERO.

Venus Concept Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VERO	45 Neutral	$4.11M	-0.04	-1371.21%	―	-13.90%	44.89%
HSCS	45 Neutral	$8.95M	―	-193.24%	―	-66.40%	65.99%
NUWE	43 Neutral	$2.83M	-0.09	―	―	-7.72%	99.54%
SINT	42 Neutral	$11.65M	-0.33	-195.48%	―	-40.47%	96.14%
AMIX	40 Underperform	$7.00M	―	-195.55%	―	―	65.72%
HIND	37 Underperform	$29.94M	-0.01	-101.49%	―	-19.81%	93.32%

Venus Concept Corporate Events

Venus Concept Reduces Debt with Equity Exchange

On September 30, 2025, Venus Concept Inc. completed a debt-to-equity exchange agreement with Madryn Health Partners, converting $11.48 million of subordinated convertible notes into 545,335 shares of Series Y preferred stock. This transaction reduced Venus Concept’s total debt by 24%, enhancing its financial position and supporting its strategic initiatives for long-term growth and profitability. The exchange agreement also involved amendments to existing loan agreements, providing additional financial flexibility and extending loan maturity dates.

The most recent analyst rating on (VERO) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Venus Concept stock, see the VERO Stock Forecast page.

Venus Concept Secures $2M Loan for Working Capital

On September 19, 2025, Venus Concept Inc. secured a twelfth delayed drawdown of $2,000,000 under its Loan and Security Agreement with Madryn Health Partners, intended for general working capital. Additionally, the board approved transaction completion bonuses for executives Rajiv De Silva and Domenic Della Penna, contingent upon the successful completion of a strategic transaction involving a change of control.

The most recent analyst rating on (VERO) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Venus Concept stock, see the VERO Stock Forecast page.

Venus Concept Secures Financial Relief with New Agreements

On August 31, 2025, Venus Concept Inc. and its subsidiaries entered into several agreements with Madryn Health Partners to address liquidity requirements and loan maturity dates. The Consent Agreement waived certain minimum liquidity requirements under the MSLP Loan Agreement through September 30, 2025, while the Nineteenth Bridge Loan Amendment extended the maturity date of the Bridge Loan to September 30, 2025. Additionally, the Notes Consent Agreement waived liquidity requirements under the 2025 Notes, also through September 30, 2025. These agreements are aimed at providing financial relief and operational flexibility to Venus Concept Inc.

The most recent analyst rating on (VERO) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Venus Concept stock, see the VERO Stock Forecast page.

Venus Concept’s Earnings Call: Mixed Results Amid Strategic Shifts

Venus Concept’s recent earnings call painted a mixed picture of their financial health. The company showcased strategic achievements, such as sequential growth and a significant business sale, yet also faced ongoing challenges with revenue and profitability. While positive steps towards financial improvement were evident, significant issues remain, including revenue declines and increased losses.

Venus Concept Secures $2M Loan for Operations

Venus Concept Inc. announced the completion of its eleventh delayed drawdown under a Loan and Security Agreement with Madryn Health Partners, amounting to $2,000,000, on August 21, 2025. This funding is intended for general working capital purposes, reflecting the company’s ongoing efforts to secure financial stability and support its operations in the competitive medical aesthetics industry.

The most recent analyst rating on (VERO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Venus Concept stock, see the VERO Stock Forecast page.

Venus Concept Reports Q2 2025 Financial Results

Venus Concept Inc. is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive aesthetic and hair restoration technologies. In its second quarter of 2025, Venus Concept reported a total revenue of $15.7 million, reflecting a 5% decrease year-over-year but a 15% increase from the previous quarter. The company saw a 5% increase in U.S. revenue, driven by a 23% growth in cash systems sales. Despite these gains, the company reported a GAAP net loss of $11.7 million, an improvement from the $19.9 million loss in the same quarter last year. Additionally, the company completed several strategic financial transactions, including equity offerings and debt-to-equity exchanges, to strengthen its balance sheet. The sale of its Venus Hair business for $20 million is part of its strategy to focus on its core medical aesthetics business. Looking ahead, Venus Concept’s management remains focused on managing cash burn, enhancing its capital structure, and pursuing strategic initiatives to achieve long-term profitability.

Venus Concept Amends Loan Agreements for Financial Relief

On July 31, 2025, Venus Concept Inc. and its subsidiaries entered into several agreements with Madryn Health Partners to amend existing loan agreements, including waiving certain liquidity requirements and extending maturity dates. These amendments, including the Eighteenth Bridge Loan Amendment on August 6, 2025, aim to provide financial relief and operational flexibility, impacting the company’s financial strategy and stakeholder interests.

Venus Concept Secures Additional $2M Bridge Financing

Venus Concept Inc. announced on July 21, 2025, the completion of its tenth delayed drawdown under a Loan and Security Agreement with Madryn Health Partners, securing an additional $2,000,000 in bridge financing. This funding, part of a larger $23,237,906.85 financing agreement, will be used for general working capital, reinforcing the company’s financial stability and operational capacity in the competitive medical aesthetics market.